A Multi-center, Open, Randomized, Parallel-group, 2 Arm Study to Compare the Efficacy and Safety of Amaryl(Rm)M 1/500mg Twice Daily Versus Amaryl® 4mg Both in Combination With Lantus(Rm) Once-daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control

Trial Profile

A Multi-center, Open, Randomized, Parallel-group, 2 Arm Study to Compare the Efficacy and Safety of Amaryl(Rm)M 1/500mg Twice Daily Versus Amaryl® 4mg Both in Combination With Lantus(Rm) Once-daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2013

At a glance

  • Drugs Glimepiride/metformin (Primary) ; Glimepiride; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Handok Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top